Company news
Atyr Pharma, Inc. (NASDAQ:ATYR) news
Atyr Pharma, Inc. news releases on 6ix. Latest, Sep 24, 2026: ATyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
Press releases & updates
ATyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
September 24, 2026
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
September 1, 2026
ATyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
August 10, 2026
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
July 15, 2026
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
May 14, 2026
aTyr Pharma to Participate in Upcoming Investor Conferences
May 13, 2026
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
May 11, 2026
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
March 4, 2026
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
February 3, 2026
aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
November 10, 2025
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
November 6, 2025
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
November 5, 2025
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
September 30, 2025
Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results
September 17, 2025
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
September 15, 2025
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 5, 2025
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update
August 7, 2025
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
July 22, 2025
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
June 26, 2025
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
June 4, 2025
aTyr Pharma to Present at Upcoming Investor Conferences
May 20, 2025
aTyr Pharma to Present at Upcoming Investor Conferences
May 19, 2025
aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
May 19, 2025
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
May 14, 2025
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
May 7, 2025
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
April 29, 2025
aTyr Pharma to Participate in April Investor Conferences
April 3, 2025
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
March 26, 2025
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
March 13, 2025
aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
March 12, 2025
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
March 6, 2025
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results
March 4, 2025
aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
February 24, 2025
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
January 28, 2025
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
December 11, 2024
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
December 9, 2024
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis
December 8, 2024
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
November 14, 2024
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
November 6, 2024
aTyr Pharma to Present at the LD Micro Main Event XVII in October
October 13, 2024
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
October 7, 2024
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
October 1, 2024
aTyr Pharma to Participate in September Investor Conferences
August 20, 2024
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
August 12, 2024
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
August 5, 2024
aTyr Pharma Announces Research Study with Stanford Medicine
July 29, 2024
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
July 21, 2024
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
June 2, 2024